The abstract describes the dose-escalation part of the ONCOS-102
and durvalumab combination trial in peritoneal malignancies
The abstract has been selected for the Poster Discussion
Session Developmental
Therapeutics-Immunotherapy to be presented 29 May at the
ASCO 2020 virtual meeting
OSLO, Norway, May 14, 2020 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors, today
announces that an abstract relating to the dose escalation part of
the ONCOS-102 and durvalumab trial in primary ovarian and
colorectal cancer that has spread to the peritoneum has been
selected for presentation at a Poster Discussion Session during
ASCO 2020.
The study is an open label, exploratory phase I/II trial
assessing the intra-peritoneally delivered ONCOS-102 in combination
with systemically administered checkpoint inhibitor durvalumab in
patients with platinum-resistant ovarian or colorectal cancers that
have metastasized to the peritoneal cavity. The trial is designed
with a dose-escalation phase assessing three different dosing
levels, followed by an expansion phase with a total of up to 78
patients enrolled into separate groups of ovarian and colorectal
cancer.
In the ASCO abstract, safety, immune activation and clinical
response data for the three dose escalation cohorts will be
presented. A total of 17 patients were enrolled, 4 in cohort A (low
dose), 5 in cohort B (middle dose) and 8 in cohort C (high dose).
No dose-limiting toxicities were observed, and the combination had
an acceptable safety profile. Therefore, the high-dose level was
selected for the expansion phase of the trial, which is currently
enrolling patients. Preliminary analyses indicate that the
treatment is triggering immune activation and has clinical
activity, which were more pronounced in cohort B and C.
Dr. Magnus Jäderberg, Chief Medical Officer of Targovax,
said: "We are very proud that ONCOS-102 was chosen as the
oncolytic virus of choice for this trial and we are equally pleased
that the scientific committee has selected our ONCOS-102 and
durvalumab combination abstract for a poster discussion at the
upcoming ASCO meeting. Although it is too early in the trial to
interpret the clinical data, we are happy to have moved into the
expansion phase following successful completion of the dose
escalation phase. This is an important clinical trial as it
addresses a disease with a very high unmet medical need while
potentially opening up intra-peritoneal administration as an
alternative delivery route for ONCOS-102."
Poster discussion
sessionAbstract title:
|
Developmental
Therapeutics-ImmunotherapyPhase I/II study to evaluate systemic
durvalumab + intraperitoneal (IP) ONCOS-102 in patients with
peritoneal disease who have epithelial ovarian (OC) or metastatic
colorectal cancer (CRC): Interim phase I clinical and translational
results.
|
Date /
time:
|
29 May 2020, 8-11AM
CDT
|
Abstract /
Poster:
|
3017 /
81
|
The abstract can be found here
https://meetinglibrary.asco.org/record/185276/abstract.
The trial is a collaboration between Targovax, AstraZeneca,
Cancer Research Institute (CRI) and Ludwig Cancer Research.
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas
Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-announces-that-the-oncos-102-and-durvalumab-abstract-is-selected-for-a-poster-discussion-se,c3111785